Current Report Filing (8-k)
June 06 2018 - 6:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) of the
SECURITIES
EXCHANGE ACT OF 1934
May
30, 2018
Date
of Report (Date of Earliest event reported)
PetLife
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-52445
|
|
33-1133537
|
(State
or other Jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
8033
Sunset Blvd., Los Angeles, CA 90046
|
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code:
|
|
(855)
682-7853
|
|
|
|
10120
So. Eastern Avenue, Suite 213, Henderson, NV 89052
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13c-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (/Section
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging
growth company [ ]
fan
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry Into a Material definitive agreement
Following
the cancellation on June 4, 2018 of the Consulting Agreement by and between Petlife
See
Pharmaceuticals, Inc. (the “Company”)
and Delta 9 Pharmaceuticals, Inc. (“Delta 9”) dated March 13, 2018 (See
Item 102 -Termination of Material Definitive
Agreement
, below), the Company entered into a Consulting Agreement with Therapeutic Solutions Group LLC, a Wyoming limited
liability company (“TSG”) on June 4, 2018, (the “TSG Agreement”). The TSG Agreement provides that TSG
will perform certain consulting services related to the management of the Company’s scorpion ranch operations (the “Ranch”)
in Haiti. For such ongoing services, TSG shall receive (i) 100,000,000 restricted shares of the Company’s common stock and
(ii) monetary payments equal to Fifty percent (50%) of the net profits derived from sales generated by the operations of the Ranch.
The foregoing description of the TSG Agreement is a summary only and is qualified in its entirety by the full text of the Agreement,
which is filed as Exhibit 1.1 hereto and incorporated herein by reference.
Item
1.02 Termination of a Material definitive agreement
On
May 30, 2018 Delta 9 gave written notice to the Company that it would be unable to perform its obligations under the Consulting
Agreement by and between the Company and Delta 9 dated March 13, 2018 and Delta 9 would return to the Company the 100,000,000
shares of restricted stock issued to Delta 9. Following receipt of that notice by the Company, the Company cancelled the agreement
with Delta 9 effective June 4, 2018. As of the date of this Current Report the Company has not yet received such shares from Delta
9 for cancellation.
Item
5.01 Change of Control of Registrant
Upon
the issuance of 100,000,000 restricted shares of common stock by the Company to TSG pursuant to the TSG Consulting Agreement (See
Item 1.01 – Entry into a Material Definitive Agreement
, above) and the cancellation of the 100,000,000 restricted
shares of common stock previously issued to Delta 9, a change of control be take place. The shares involved in the transactions
constitute approximately 65% of the Company’s currently issued and outstanding shares of common stock.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
Effective
May 30, 2018, Laura De Leon Castro resigned as Chief Executive Office, President, Secretary, Treasurer, Chief Financial Officer,
and a Director of the Company. Ms. De Leon Castro’s resignation was not the result of any disagreements with the Company
regarding our operations, policies, practices or otherwise. Concurrently, Sebastian Serrell-Watts was appointed Chief Executive
Officer, President, Secretary, Treasurer, Chief Financial Officer, and Chairman of the Board of Directors of the Company.
Sebastian
Serrell-Watts - Chief Executive Officer, President, Secretary, Treasurer, Principal Financial Officer, and Chairman of the Board
of Directors
Sebastian
Serrell-Watts, 53, is a graduate of the University of Southern California (BA, Film Production, emphasis in Business Finance).
Mr. Serrell-Watts has more than 20 years of business experience spanning manufacturing, pharmaceuticals, financial services, and
entertainment, with expertise in capital raising, finance structure, sales, marketing, IPO execution, M&A. From June 2009
through December 2012, Mr. Serrell-Watts was a financial advisor with Kovack Securities. Beginning in January 2012 served as Executive
Vice President and a Board member of Medolife Corp until November 2015.. He served in the same capacities at Medolife’s
spin-off entity, publicly-traded PetLife Pharmaceuticals, Inc., through November 2015. From November 2015 to present, Mr. Serrell-Watts
has served as Chief Operating Officer and a Board member of Eclectic Pictures. From May 2016 to present he has service as a Consultant
to DIVA Pharmaceuticals, Inc. He has also served as Consultant to Calmare Therapeutics, Inc. from December 2017 to present.
The
Company believes that Mr. Serrell-Watts educational backgrounds and business and operational experiences give him the qualifications
and skills to serve as a Director and in his respective officer positions.
Mr.
Serrell-Watts has not been involved in a transaction with related persons, promoters or control persons during the Company’s
preceding fiscal year.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on
Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
June 5, 2018
|
PETLIFE
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Sebastian Serrell-Watts
|
|
Name:
|
Sebastian
Serrell-Watts
|
|
Title:
|
President
and Chief Executive Officer
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Apr 2023 to Apr 2024